CA-ZYNGA
16.7.2020 15:02:09 CEST | Business Wire | Press release
Zynga Inc. (Nasdaq:ZNGA), a global leader in interactive entertainment, today announced that Noel Watson, Chief Financial Officer at TrueCar Inc., joined the company's Board as an independent director. A skilled executive with a wealth of experience in building digital services and leading teams, Noel Watson becomes the ninth member of Zynga's Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005015/en/
“Noel brings to Zynga more than 20 years of successful financial and operating leadership,” said Frank Gibeau, Chief Executive Officer at Zynga. “His extensive experience with high growth digital services and strong track record with mergers and acquisitions will be powerful additions to our company. We are excited to welcome Noel to Zynga’s Board of Directors and Audit Committee.”
Mr. Watson joined TrueCar Inc., a leading automotive digital marketplace focused on creating the most innovative and efficient experience for car buyers, in 2019 as the company’s CFO, leading financial operations including accounting and investor relations. Prior to TrueCar, Mr. Watson held the position of Chief Accounting Officer at TripAdvisor Inc., the world’s largest travel platform with over 400 million unique monthly site visitors. He began his career as a certified public accountant at Arthur Andersen LLP and subsequently held management positions at Boston based technology firms ArrAy Inc. and Way Systems prior to joining TripAdvisor in 2006. Mr. Watson holds a bachelor’s degree in accounting from Bryant University.
“I am excited to be joining Zynga’s Board of Directors during this dynamic period of growth for the company in its mission to connect the world through games,” said Noel Watson. “With the increasing penetration and use of mobile phones, and the more than 2.5 billion people globally playing games by the end of 2020, Zynga is incredibly well positioned to be a force in digital entertainment, built around iconic brands and experiences that people love.”
“After months of conversation, I could not be more pleased that Noel Watson is joining Zynga’s Board of Directors,” said Ellen Siminoff, Director and Chair of the Nominating and Governance Committee at Zynga. “With more growth ahead for Zynga, Noel’s experience and perspective will be instrumental in our continued success. Noel brings with him a proven ability to lead and execute, and his point of view will be invaluable for our company.”
Zynga's distinguished Board members include Frank Gibeau, Regina Dugan, William "Bing" Gordon, Louis Lavigne Jr., Carol Mills, Mark Pincus, Janice Roberts, and Ellen Siminoff. On Zynga's Board, Mr. Watson will serve on the Audit Committee alongside members Louis Lavigne, Jr., Carol Mills, and Ellen Siminoff.
Editor’s Note:
Key art and photography assets available for use = https://bit.ly/ZyngaBODAnnouncement
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR RacingTM , Empires & PuzzlesTM , Merge Dragons!TM , Merge Magic!TM , Toon Blast™, Toy Blast™, Words With FriendsTM and Zynga PokerTM . Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .
Forward-Looking Statements
This press release contains forward-looking statements regarding our expectations related to growth in Zynga’s business and the mobile game industry. Forward-looking statements often include words such as “next,” “intend,” “will,” “anticipate,” “believe,” “ahead,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s web site at www.sec.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
